Earnings ·
Elite Pharmaceuticals, Inc. filed a Form 10-Q for the first quarter ended June 30, 2027, and issued a press release…
ELTPElite Pharmaceuticals Inc
Elite Pharmaceuticals, Inc. filed a Form 10-Q for the first quarter ended June 30, 2027, and issued a press release announcing financial results on August 13, 2026. Consolidated revenues decreased 19.5% to $32.4 million from $40.3 million in the prior year period, primarily due to lower margins on its generic Vyvanse product line amid competitive market adjustments. Income from operations fell 65% to $7.5 million, while net income attributable to common shareholders was $5.9 million. Management will host a conference call on August 14, 2026, at 11:30 AM EDT to discuss the results and provide a business update. Elite Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic oral drug products.